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Abstract
Mesenchymal stem cells (MSCs) have been investigated as a potential injectable ther-
apy for the treatment of knee osteoarthritis, with some evidence of success in pre-
liminary human trials. However, optimization and scale-up of this therapeutic
approach depends on the identification of functional markers that are linked to their
mechanism of action. One possible mechanism is through their chondrogenic differ-
entiation and direct role in neo-cartilage synthesis. Alternatively, they could remain
undifferentiated and act through the release of trophic factors that stimulate endoge-
nous repair processes within the joint. Here, we show that extensive in vitro aging of
bone marrow-derived human MSCs leads to loss of chondrogenesis but no reduction
in trophic repair, thereby separating out the two modes of action. By integrating
transcriptomic and proteomic data using Ingenuity Pathway Analysis, we found that
reduced chondrogenesis with passage is linked to downregulation of the FOXM1 sig-
naling pathway while maintenance of trophic repair is linked to CXCL12. In an
attempt at developing functional markers of MSC potency, we identified loss of
mRNA expression for MMP13 as correlating with loss of chondrogenic potential of
MSCs and continued secretion of high levels of TIMP1 protein as correlating with
the maintenance of trophic repair capacity. Since an allogeneic injectable osteoar
therapy would require extensive cell expansion in vitro, we conclude that early pas-
sage MMP13+, TIMP1-secretinghigh MSCs should be used for autologous OA thera-
pies designed to act through engraftment and chondrogenesis, while later passage
MMP13−, TIMP1-secretinghigh MSCs could be exploited for allogeneic OA therapies
designed to act through trophic repair.
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1 | INTRODUCTION
The concept of multipotent mesenchymal stem cells (MSCs) was
established by Caplan in the early 1990s1 following the seminal work
of Friedenstein in the 1960s and 1970s, demonstrating the presence
of osteogenic precursor cells in bone marrow.2-4 Building on this early
work, there have been many studies demonstrating the capacity of
MSCs to differentiate in vitro with clear evidence for multipotent
skeletal lineage differentiation,5 including chondrogenesis,6-13 osteo-
genesis,14-17 and adipogenesis9,18,19 as well as more limited evidence
for pluripotent differentiation including endodermal and ectodermal
pathways.1,20 In one of these studies, we generated clonal populations
of bone marrow MSCs and showed that individual cells retained the
capacity for chondrogenesis, with varying degrees of potency.9
More recently, evidence has grown that MSCs may support tissue
repair through mechanisms that do not directly relate to their multipo-
tential differentiation capacity.21 Caplan has described MSCs as having
“trophic” capacity by which, following implantation, they induce neigh-
boring cells to secrete active molecules, for example, in the treatment
of stroke, myocardial infarction, or in meniscal cartilage repair.22 Trophic
repair is most likely mediated through the production by MSCs of large
amounts of growth factors and other mediators.20,22-25 We have previ-
ously developed a therapeutic strategy for meniscal cartilage repair
based on the trophic properties of MSCs26 that has shown some evi-
dence of efficacy in preclinical and clinical trials.27 A second mechanism
contributing to trophic repair is the ability of MSCs to suppress immune
responses by a range of mechanisms including downregulation of T cell
proliferation.9,24,28-31 This important property of MSCs has been used
clinically to support the engraftment of donated hematopoietic cells
and to prevent graft vs host disease.24,32
There have been several studies describing the loss of differentia-
tion capacity with increasing passage of MSCs in vitro,33-36 with other
studies suggesting that in vivo aging also leads to a loss of differentia-
tion capacity after ex vivo isolation of the aged cells.37-39 These obser-
vations combined with parallel observations of shortening in telomere
length with in vitro aging of MSCs40 have been interpreted as indicating
a rapid senescence process that compromises cell function and limits
their clinical utility. Conversely, no comparative aging-related data have
been reported for trophic repair or immunoregulation.
The aim of this study was to identify markers of MSC
chondrogenic potency (measured by cartilage tissue engineering) and
trophic potency (measured by meniscal cartilage integration as well as
by suppression of T-cell proliferation), using extensive in vitro aging of
the cells as a method of regulating their specific functional activity.
2 | MATERIALS AND METHODS
2.1 | Isolation and expansion of human marrow-
derived MSCs for in vitro studies
The model used as the basis for all the experiments reported here was
long-term culture of human bone marrow-derived MSCs. Bone
marrow plugs were collected from the femoral heads of patients
undergoing total hip replacement. All patients gave their informed
consent and the study was carried out according to local ethical
guidelines (North Bristol NHS Trust Research Ethics Committee).
Patient details can be seen in Table S1. Cells were suspended in stem
cell expansion medium consisting of low glucose Dulbecco's Modified
Eagles Medium (Sigma-Aldrich) supplemented with 10 vol%/vol% fetal
bovine serum (FBS, Sigma-Aldrich), 1 vol%/vol% Glutamax (Gibco),
and 1 vol%/vol% Penicillin/Streptomycin (Sigma-Aldrich). The serum
batch was selected to promote the growth and differentiation of
MSCs.41 The medium was also supplemented with 10 ng/mL FGF-2
(Peprotech). This growth factor has been previously shown to
enhance the MSC proliferation rate in vitro,12,42 to retain MSCs as
undifferentiated cells during proliferation6,43 and to enhance
chondrogenic differentiation when the FGF-2 expanded MSCs are
subsequently exposed to differentiation conditions.12,42 The cell sus-
pension was separated from any bone in the sample by repeated
washing with media. The cells were centrifuged at 500g for 5 minutes
and the supernatant/fat removed. The resulting cell pellet was
resuspended in medium, and then plated at a seeding density of
between 1.5 × 105 and 2.0 × 105 nucleated cells per cm2. These
flasks were incubated at 37C in a humidified atmosphere of 5% CO2
and 95% air. Four days were allowed before the first medium change
and then the medium was changed every other day until adherent
cells reached 90% confluence and were ready for passaging.
2.2 | Cell passaging and calculation of population
doublings and doubling time
At the end of each passage, the MSCs were harvested using 0.25%
trypsin-EDTA (Sigma-Aldrich), pooled, counted, and then divided into
different centrifuge tubes for reseeding and further growth, for imme-
diate use in measurement of % integration of meniscal cartilage, for
storage in liquid nitrogen for subsequent use in differentiation proto-
cols as well as for genomic and proteomic analysis. The cells for each
Significance statement
This study has shown that mesenchymal stem cell (MSC) cho-
ndrogenesis is a transient property of these cells which is lost
as they age in vitro, whereas trophic repair potency is
maintained until the MSCs cease to grow. These findings are
significant as they highlight the importance of defining the
intended mode of action when preparing MSCs for injection
into osteoarthritic joints. These studies demonstrate that the
development of injectable MSC therapies for osteoarthritis
must take into account the transient nature of chondrogenic
potency relative to their sustained trophic potency with
increasing passage and specific strategies should be adopted
to exploit one or other of these mechanisms of action.
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patient were passaged continuously without freezing, until growth
arrest, defined as no detectable increase in cell number between pas-
sages (see Table S1). At each passage, the total number of harvested
MSCs was determined. The first cell harvest after seeding of fresh
bone marrow was taken as passage 0. The number of cells reseeded
at the start of passage 1 was used as the baseline for calculation of
the first population doubling (PD) value at the end of passage 1.
Downstream analyses of the MSCs were undertaken from passage 1
onward.
The number of PDs was calculated using the following formula:
PDs = log Number of HarvestedMSCsð Þ− log Number of seededMSCsð Þ½ =log 2ð Þ
The PD for each passage was calculated and added to the PD of
the previous passages to generate data for Cumulative PD at each
passage.
Population doubling time (PDT) was calculated for each passage
using the formula:
PDT= t× log 2ð Þ=log cells harvested=cells seededð Þ
where t = the time between cell seeding and cell harvesting.
2.3 | Detection of cell-surface phenotypic markers
MSCs (100 000 cells from each patient at each of passages 1, 5, 10, and
15) were suspended in a 1:500 dilution of Zombie (Biolegend), a live/
dead cell dye, and incubated for 20 minutes in the dark. Nonspecific
antigens were then blocked by incubating the cells at room temperature
for 1 hour in 1 wt%/vol% bovine serum albumin (Sigma-Aldrich), 5 vol
%/vol% FBS. The cells were washed by centrifugation in three volumes
of Dulbecco's phosphate-buffered saline (PBS; Sigma-Aldrich), and the
cell pellet was suspended in 100 μL of a primary antibody solution con-
taining 20 to 100 μg/mL of antibody in blocking solution. All the pri-
mary antibodies were fluorescent-labeled mouse anti-human IgGs: anti-
CD105-fluorescein isothiocyanate (FITC), anti-CD90-phycoerythrin
(PE), and anti-CD45-PE were from R&D Systems; anti-CD34-FITC was
from eBioscience, Life Technologies; IgG1-FITC and IgG1-PE isotype
controls were from R&D Systems. After incubation for 40 minutes at
4C, the cells were washed and suspended in 1 mL of PBS for analysis
on a Canto flow cytometer (BD FACSCanto II), after the exclusion of
nonviable cells. Data were analyzed using FlowJo (Treestar). Positive
expression was defined as the level of fluorescence greater than 95% of
corresponding isotype-matched control antibodies.
2.4 | Chondrogenesis
2.4.1 | Cartilage tissue engineering
The chondrogenic capacity of MSCs from each passage was
assessed by performing three-dimensional cartilage tissue
engineering, as previously described.41 Briefly, 300 000 cells were
loaded drop-wise onto 5 mm diameter × 2 mm thick polyglycolic
acid scaffold disks (Biomedical Structures) which had been pre-
coated with 100 μg/mL fibronectin (Sigma-Aldrich). Constructs
were then cultured in chondrogenic differentiation medium con-
sisting of Dulbecco's Modified Eagle Medium (DMEM) containing
4500 mg/L (high) glucose (Sigma-Aldrich), supplemented with
10 ng/mL transforming growth factor-β3 (R&D Systems), 100 nM
dexamethasone, 80 μM ascorbic acid 2-phosphate, 1 mM sodium
pyruvate, 1 vol%/vol% Penicillin/Streptomycin (all from Sigma-
Aldrich), 1% insulin-transferrin-selenium-G (ITS), and 2 mM Glu-
tamax (both from Gibco). After 7 days, the medium was further
supplemented with 10 μg/mL human insulin (Sigma-Aldrich) until
the end of culture. The constructs were incubated at 37C for a
total of 35 days on a rotating platform and medium was changed
every 3 days.
2.4.2 | Biochemical analysis
Cartilage constructs were freeze-dried and weighed at the end of
the 35-day tissue engineering period. The extracellular matrix was
fully solubilized by overnight digestion with 2 mg/mL bovine pan-
creatic trypsin (Sigma-Aldrich) which was then boiled for
15 minutes to inhibit the action of the enzyme.44 In order to obtain
the dry weight of extracellular matrix in the construct, remaining
undigested scaffold material was freeze-dried, weighed, and sub-
tracted from the original dry weight. The amounts of proteoglycan
in the digests was measured as sulfated glycosaminoglycan (GAG)
using a dimethylmethylene blue (Sigma-Aldrich) colorimetric
assay.45
2.5 | Osteogenesis and adipogenesis
Whole MSC populations or MSC clones were grown in monolayer
until 50% to 70% confluent prior to osteogenic differentiation or
100% confluent prior to adipogenic differentiation. In both cases, con-
trol cells were then cultured in minimum essential medium (α-MEM;
Sigma-Aldrich) basal medium containing 10% FBS, 1 vol%/vol% Peni-
cillin/Streptomycin, and 2 mM Glutamax. Cells stimulated to undergo
differentiation were cultured in basal medium containing either osteo-
genic supplement or adipogenic supplement (both from R&D Systems)
for 21 days. Following osteogenic differentiation cells were fixed in
70% ethanol and stained with 40 mM alizarin red S (Sigma-Aldrich),
pH 4.1, for 5 minutes. Following adipogenic differentiation cells were
fixed in 4% paraformaldehyde and stained with 0.3% oil red O (Sigma-
Aldrich) for 30 minutes. The extent of differentiation was scored
under blind conditions and classified as − (no staining), +, ++, or +++
according to increasing area and number of mineralized deposits fol-
lowing osteogenic differentiation (see Figure S1) and increasing num-
ber of lipid droplets following adipogenic differentiation (see
Figure S3).
SALERNO ET AL. 3
2.6 | Meniscal repair
2.6.1 | Preparation of sheep meniscal cartilage
Sheep legs were purchased from Edge & Son Butchers, Wirral, Mer-
seyside and the meniscal cartilage removed under sterile conditions.
Meniscal cartilage cylinders (5.0 mm in diameter and 3.0 mm thick)
were harvested from the avascular (white zone) of the ovine menisci
using a dermal biopsy punch. They were rinsed and incubated with
PBS containing 10 vol%/vol% penicillin/streptomycin and 1 vol%/vol
%, 250 μg/mL Amphotericin B (Sigma-Aldrich) for 20 minutes. Viabil-
ity of the fibrocartilage disks was maintained by culture in basic
medium consisting of low-glucose DMEM with 10 mM Hepes buffer
(Sigma-Aldrich), 1 vol%/vol% penicillin/streptomycin, nonessential
amino acids (Sigma-Aldrich), 1 vol%/vol% Glutamax, and 10%
amphotericin B at 37C in a 5% CO2 environment. The explants were
used in the integration experiments within 3 days of culture.
2.6.2 | Cell seeding
Collagen scaffolds (Ultrafoam Collagen Sponge; Bard) were cut into
6 mm diameter disks and seeded with human MSCs at a concentra-
tion of 1 × 106 cells/cm2. The suspension was loaded drop wise onto
the scaffold placed in ultra-low attachment wells of a 24-well plate
(Corning). After 4 hours, 1.5 mL of expansion medium containing
10 ng/mL FGF-2 was added and changed daily. Seeded scaffolds were
incubated for 48 hours at 37C in an orbital shaker at 50 rpm.
2.6.3 | Assembling and culture of constructs
Sandwich constructs of two ovine meniscal cartilage disks interposed with
a seeded scaffold were assembled as previously described27 using skin
clips and cultured in vitro in ultra-low attachment 6-well plates in expan-
sion medium with 10 ng/mL FGF-2 for 7 days followed by culture in an
integration medium consisting of high glucose DMEM containing 10 vol
%/vol% FBS, 1 vol%/vol% Glutamax, 1 vol%/vol% penicillin/streptomy-
cin, insulin, and 80 μM ascorbic acid 2-phosphate for 33 days. The
medium was replenished twice every week. The constructs were incu-
bated at 37C on a rotating platform throughout the culture period. At
the end of culture, the constructs were prepared for histological analysis
by fixation in 10 vol%/vol% neutral buffered formalin (Sigma-Aldrich).
2.6.4 | Histomorphometric analysis
Histomorphometry was carried out using a method that we developed
and characterized in previous studies.26,27,46 Fixed constructs were
dehydrated and paraffin embedded. Samples were cut into 4 μm sec-
tions and stained with H&E for the study of morphological details. All
histological sections were scanned using a Leica Aperio slide scanner
and histomorphometric analysis was performed under blind conditions,
using ImageScope software (Leica). Two perpendicular sections, one at
the edge and another one at the center of each construct, were used.
For each section, the entire length of the implant/meniscus interface
was measured, as well as the length of any areas of integration at the
interface. The repair index was then determined as:
%Integration = Length of integrated interface=Total interface length×100
2.7 | Immunosuppression
Human peripheral blood mononuclear cells (PBMCs) were isolated
from donor blood samples from healthy volunteers. All the volunteers
gave their informed consent and the study was carried out according
to local ethical guidelines (University of Liverpool Research Ethics
sub-committee for Physical Interventions). PBMCs were isolated by
centrifugation of the blood on 1.077 g/mL Ficoll-Paque PLUS (GE
Healthcare Life Sciences) and cultured in RPMI-1640 containing L-
glutamine (Sigma-Aldrich) and supplemented with 10% Human AB
Serum (Sigma-Aldrich) and 1 vol%/vol% Penicillin/Streptomycin.
PBMCs were stained with CellTrace Violet (ThermoFisher) to monitor
T-cell proliferation. Labeled PBMCs were then stimulated with
3.75 μg/mL anti-human CD3 (HIT3a) and 2 μg/mL anti-human CD28
(CD28.2) (both from Fisher Scientific Affymetrix eBioscience) and
cocultured with MSCs from four individual donors at passages 1, 5,
10, and 15 for 72 hours. The T-cell proliferation profile for each popu-
lation was analyzed by flow cytometry following exclusion of non-
viable cells stained with 7-amino-actinomycin D (7-AAD; BD
Biosciences).
2.8 | Quantitative PCR
Real-time quantitative polymerase chain reaction (RT-qPCR) for
MMP13 mRNA and for the housekeeping gene Tata Binding Protein
(RBP) was performed using the CellsDirect One-Step qRT-PCR Kit
(ThermoFisher), with which reverse transcription and PCR amplifica-
tions were performed in the same reaction tube. Primers specific for
MMP13 (Hs00942584_m1) and TBP (Hs00427621_m1) were pur-
chased from ThermoFisher TaqMan. The reaction was started by syn-
thesizing cDNA at 50C for 15 minutes, followed by 2 minutes at
95C to denature RNA-cDNA hybrids and deactivate reverse tran-
scriptase. The thermal cycling program consisted of 50C for
15 minutes, 95C for 2 minutes, and 40 two-step cycles of 95C for
10 seconds and 60C for 30 seconds. MMP13 expression relative to
TBP was determined at each of four time points for each MSC sample
and the results normalized to the time (passage 2), which was taken as
a Fold-expression of 1.0.
2.9 | TIMP-1 ELISA
TIMP-1 protein was measured in the secretome of MSCs using the
Quantikine enzyme-linked immunosorbent assay (ELISA) Kit for
4
human TIMP-1 (R&D Systems). MSCs were seeded into 6-well plates
at 2.25 million cells/well (three replicates) and cultured in 2 mL of
DMEM for 24 hours. The medium was then replaced with 1 mL of
phenol-free culture medium for a further 24 hours, after which the
secretome was collected and assayed at appropriate dilution using the
ELISA kit.
2.10 | Acquisition of genomic and proteomic data
2.10.1 | Transcriptomics
Transcriptomics was performed by the Centre for Genomic Research
on mRNA extracted from the mRNA of all four patients at P1, P5,
P10, and P15. When MSCs were harvested at the end of each pas-
sage, 1 × 106 cells were isolated and resuspended in RNAprotect Cell
Reagent (Qiagen). The cells were stored at −80C until the complete
set of samples from all donors and time points had been collected.
RNA was then extracted from selected time points using the RNeasy
Plus Mini Kit (Qiagen), according to the manufacturer's instructions.
The concentration of RNA in the extract was determined using a
NanoDrop 2000 spectrophotometer (Thermo). Extracted RNA was
stored at −80C prior to analysis.
Ribosomal RNA depletion was performed using the Ribo-Zero H/
M/R Kit (New England Biolabs) and RNASeq libraries were then pre-
pared using the NEB Next Ultra Directional RNA Library Prep Kit
(New England Biolabs). Paired-end sequencing of the RNASeq librar-
ies was performed by the Illumina HiSeq4000 platform using V4
chemistry.
2.10.2 | Proteomics
Proteomics was performed on secretome prepared from the MSCs of
all four patients at P1, P5, P10, and P15. When MSCs were harvested
at the end of each passage, 1 × 106 cells were isolated and
resuspended in 4 mL of serum-free, phenol red-free DMEM sup-
plemented with 4500 mg/L (high) glucose (Sigma-Aldrich), 1 vol%/vol
% Glutamax, and 1 vol%/vol% Penicillin/Streptomycin for 24 hours at
37C. The conditioned medium recovered at the end of the incubation
was harvested from each flask and stored at −80C prior to analysis.
Proteomic analysis of the secretome samples was undertaken in
the “Centre for Proteome Research” facility at the University of Liver-
pool. Protein solutions were concentrated by adding consecutive
1 mL aliquots of each sample to 10 μL of Strataclean beads (Agilent).
After each aliquot had been added, the sample was vortexed for
1 minute, centrifuged at 2000g for 2 minutes and the protein-
depleted supernatant removed. After the final aliquot had been
added, the beads were washed two times with 1 mL of 25 mM ammo-
nium bicarbonate (ambic) prior to digestion. For on-bead digestion,
the beads were resuspended in 80 μL of 25 mM ambic and 5 μL of
1 wt%/vol% Rapigest (Waters) was added. The samples were heated
at 80C for 10 minutes and then reduced by the addition of 5 μL of
9.2 mg/mL dithiothreitol (Roche) in 25 mM ambic and heating at 60C
for 10 minutes. Following cooling, 5 μL of 33 mg/mL iodoacetamide
(Sigma-Aldrich) in 25 mM ambic was added and the samples incubated
at room temperature for 30 minutes in the dark. Porcine trypsin
(sequencing grade, Promega) (1 μg) was added and the sample was
incubated at 37C overnight on a rotary mixer. The digests were acidi-
fied by the addition of 1 μL of trifluoracetic acid (TFA) and incubated
at 37C for 45 minutes. Samples were then centrifuged at 17 200g
for 30 minutes and supernatants transferred to 0.5 mL low-binding
tubes. They were centrifuged for a further 30 minutes and 10 μL
transferred to total recovery vials for liquid chromatography–mass
spectrometry (LC-MS) analysis.
Data-dependent LC-MS analyses were conducted on a QExactive
HF quadrupole-Orbitrap mass spectrometer coupled to a Dionex Ulti-
mate 3000 RSLC nano-liquid chromatograph (Hemel Hempstead, UK).
Sample digest (1-2 μL) was loaded onto a trapping column (Acclaim
PepMap 100 C18, 75 μm × 2 cm, 3 μm packing material, 100 Å) using
a loading buffer of 0.1 vol%/vol% TFA, 2 vol%/vol% acetonitrile in
water for 7 minutes at a flow rate of 12 μL min−1. The trapping col-
umn was then set in-line with an analytical column (EASY-Spray
PepMap RSLC C18, 75 μm × 50 cm, 2 μm packing material, 100 Å)
and the peptides eluted using a linear gradient of 96.2% A (0.1 vol
%/vol% formic acid): 3.8% B (0.1 vol%/vol% formic acid in water : ace-
tonitrile [80:20] [vol/vol]) to 50% A:50% B over 90 minutes at a flow
rate of 300 nL min−1, followed by washing at 1% A: 99% B for 5
minutes and re-equilibration of the column to starting conditions. The
column was maintained at 40C, and the effluent introduced directly
into the integrated nano-electrospray ionization source operating in
positive ion mode. The mass spectrometer was operated in data
dependent acquisition mode with survey scans between m/z 350-
2000 acquired at a mass resolution of 60 000 (full width at half maxi-
mum) at m/z 200. The maximum injection time was 100 ms, and the
automatic gain control was set to 3e6. The 16 most intense precursor
ions with charges states of between 2+ and 5+ were selected for MS/
MS with an isolation window of 2 m/z units. The maximum injection
time was 45 ms, and the automatic gain control was set to 1e5. Frag-
mentation of the peptides was by higher-energy collisional dissocia-
tion using a normalized collision energy of 30%. Dynamic exclusion of
m/z values to prevent repeated fragmentation of the same peptide
was used with an exclusion time of 20 seconds. Raw data files from
the mass spectrometry were imported into Progenesis QI for Proteo-
mics v.2.0 software (Waters Ltd, Newcastle upon Tyne, UK) for align-
ment and peak detection. An aggregate file was generated which
contained all the peaks from all runs in an experiment so that there
were no missing values. The data were filtered and charges +1 and
≥ +8 were removed. The msms fragmentation data were searched
against the UniProt human reviewed DB using Mascot v. 2.4.1 soft-
ware (Matrix Science, London, UK). The precursor ion mass tolerance
was set to 10 ppm and the product ion tolerance to 0.01 Da. Oxida-
tion of methionine was selected as a dynamic modification and car-
bamidomethyl cysteine as a fixed modification. One missed cleavage
was permitted. The Mascot search returned 2594 proteins at 2.17%
false discovery rate (FDR: psms above homology). A 1% FDR was set
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and 2366 proteins were exported as an .xml file (FDR type: distinct
psms) and imported into Progenesis and peptides assigned to proteins.
Protein quantification was based on averaging the individual abun-
dances for each protein per donor at each passage and comparing
proteins that were differentially expressed between the four
passages.
2.11 | Quantification and statistical analysis
2.11.1 | Bioinformatics
Data processing, integration and analyses were undertaken by the
Computational Biology Facility at the University of Liverpool. RNAseq
data were acquired as described above. The raw Fastq files were
trimmed for the presence of Illumina adapter sequences using
Cutadapt version 1.2.1, option -O 3. Reads were further trimmed
using Sickle version 1.200 with a minimum window quality score of
20. Reads shorter than 10 base pairs after trimming were removed.
Sequence quality metrics were assessed using FastQC version 0.11.4.
No samples were removed. Sequence data were aligned to the human
genome version GRCh38 from NCBI using Bowtie2 version 1.1.2 with
recommended parameters.47 Gene level count data were generated
from the Bowtie2 alignments using htseq-count version 0.9.0. The R
library DESeq2 was used to produce rlog transformed count data.
These were filtered to remove genes with less than 1 average count.
Statistical analyses were performed in R version 3.4.4 and graphical
representations were done using the R package ggplot2.
Normalized proteomics and transcriptomics data were integrated
and preliminary exploratory analyses revealed a relevant heterogene-
ity between patients. In order to discriminate between changes
related to patient heterogeneity and changes related to passage, dif-
ferentially expressed variables over passage were calculated with a
two-way analysis of variance (ANOVA) to account for patient variabil-
ity as confounder. This followed multiple testing corrections using the
Benjamin-Hochberg method. Significant variables (338 of which 38
were proteins and 300 were genes) uniquely over passage were
selected for further analysis in the Ingenuity Pathway Database (IPA,
Qiagen, Analysis 2015).
Base 2 log fold changes of the 338 significant variables were cal-
culated with respect to passage 1 and used for a IPA (Qiagen), where
analysis was performed according to the manual to predict possible
upstream regulators involved in the changes observed, possible path-
ways affected and a number of functions and terms significantly
enriched (database access on 9 December 2018). IPA was also used
to download knowledge terms involved in selected key processes,
that is, (a) Cell migration in MSCs, (b) cell movement in MSCs, and (c)
wound healing. All these variables were mapped to our experimental
F IGURE 1 Growth and phenotypic characteristics of MSCs from four patients. A, The number of population doublings reached after each
passage using MSCs from each patient was recorded until growth ceased (for PN242 data were collected until passage 30, when the cells
continued to grow). B, The population doubling time is shown up to passage 17 for all four patients. C, Typical cell morphology is shown for
PN251 MSCs at passage 4 and passage 16 (growth arrest was at passage 17 for this patient) and for PN242 at passage 19 (no growth arrest
observed for this patient). Scale bars = 200 μm. D, The percentage of cells expressing MSC markers CD90 and CD105 and hematopoietic stem
cell markers CD34 and CD45 were determined by fluorescence-activated cell sorting. MSCs, mesenchymal stem cells
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data. Then we assessed the number of variables changing over pas-
sage within these terms and contextualize the biological findings.
Principal component analysis (PCA) was performed in mean cen-
tered and scaled data via singular value decomposition using the func-
tion prcomp within the statistical software R.
2.11.2 | Statistics
Differentiation variables (Tissue engineering, GAG, and osteogenesis and
adipogenesis scores) were compared over passage by calculating the non-
parametric Spearman correlation embedded in the function cor.test
within the stats package in R. Osteogenesis and adipogenesis capabilities
were measured with semiquantitative data based on image analysis.
These were translated into integers 0 to 1 to undertake the calculation.
3 | RESULTS
3.1 | Patient characteristics and MSC growth
potential
Bone marrow was collected from patients undergoing knee or hip
arthroplasty. All patients gave informed consent and the study was
performed in full accordance with local ethics guidelines (Southmead
Research Ethics Committee Ref 078/01). Table S1 shows the patient
characteristics. All four were male with a mean age of 49 years (range:
38-70 years) at the time of operation. MSCs were isolated from each
bone marrow by plastic adhesion and grown under standard culture
conditions until they failed to proliferate any further. MSCs from
PN241 and PN242 continued to proliferate for a larger number of
passages than MSCs from PN251 and PN264, with PN242 cells
showing no sign of growth arrest even at passage 30 (Figure 1A and
Table S1). Figure 1B shows the MSC PDT at each passage for each
patient up to passage 17. The PDT of MSCs from all four patients was
similar at early passages and became longer at later passages, with
MSCs from one patient (PN264) showing particularly slow growth at
higher passage numbers. Early passage MSCs had a typical small size
and stellate appearance, but became larger and less spindly as the
cells became more senescent (Figure 1C, PN251). However, PN242
cells had a small size and spindly, stellate appearance even at very
high passage number, when they were continuing to proliferate well
(Figure 1C, PN242). These results are consistent with previous studies
showing that cell enlargement and loss of stellate shape are associ-
ated with increased senescence.34
Cell surface marker expression was determined by fluorescence-
activated cell sorting (FACS) using MSCs from all four patients at each
of passages P1, P5, P10, and P15. The expression of MSC markers
F IGURE 2 Macroscopic appearance of tissue engineered cartilage made using MSCs from four patients at multiple passages. MSCs from
passages 2 to 16 were seeded onto polyglycolic acid scaffolds before being induced to undergo chondrogenic differentiation. Each image shows
replicate samples from each patient at each passage that was investigated. MSCs, mesenchymal stem cells
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CD105 and CD90 was maintained at >90% at late passage in MSCs
from all four patients. Hematopoietic stem cell marker CD45
remained at <10% at all passages; however, there was a small increase
in the expression of hematopoietic stem cell marker CD34 with
increasing passage number in two of the patients (Figure 1D).
3.2 | The tri-lineage differentiation potential of
MSCs falls with increasing passage
MSCs from selected passages of each patient were tested for their
chondrogenic potential in a three-dimensional cartilage tissue engi-
neering assay, with the amount of engineered cartilage measured as
the dry weight of tissue and quality of the cartilage measured as the
GAG content expressed as a percentage of dry weight. There was
clear evidence of a loss of chondrogenic potential with in vitro aging
of the cells. The typical macroscopic appearance of tissue engineered
cartilage over a range of passages for MSCs from each of the patients
can be seen in Figure 2, clearly demonstrating a reduction in the aver-
age size of cartilage constructs when produced using late passage
MSCs. This macroscopic observation was supported by quantitative
analysis. There was a significant negative correlation between the
mean dry weight of cartilage formed and the cumulative population
doublings of MSCs recorded at the time of tissue engineering for
three out of the four patients and a significant negative correlation
between the mean cartilage GAG content and the cumulative popula-
tion doublings of MSCs recorded at the time of tissue engineering for
all four patients (Figure 3A-D). Furthermore, both the dry weight and
the GAG content of all the individual tissue engineered cartilage con-
structs were significantly negatively correlated with the passage num-
ber of the MSCs used for tissue engineering (Figure 3E,F).
MSCs were also tested for their osteogenic potential in mono-
layer culture by semiquantitative analysis of the staining for alizarin
red. Typical images of the staining patterns and the scoring systems
used are shown in Figure S1. There was some evidence of a gradual
loss of osteogenic potency of MSCs; however, the results were incon-
sistent between patients. For patient PN241, there was no apparent
change in the mean osteogenic score with cumulative population dou-
blings (Figure S2A). For patient PN242, there was a significant fall in
osteogenic potential with cumulative population doublings
F IGURE 3 Biochemical properties of tissue engineered cartilage made using MSCs from four patients at multiple passages. MSCs from each
patient across a range of passages were used to tissue engineer cartilage, as shown in Figure 2. A-D, The relationship between dry weight or GAG
content of tissue engineered cartilage constructs and the population doublings of MSCs at the time of tissue engineering are shown for each of
the patients. For all the graphs, each point shows the mean value of multiple tissue engineering replicates made using cells from one patient at a
single passage. E, The relationship between dry weight of tissue engineered cartilage constructs and the passage number of MSCs at the time of
tissue engineering are shown for all four patients. Each point is the result for a single replicate sample. F, The relationship between the GAG
content of tissue engineered cartilage constructs and the passage number of MSCs at the time of tissue engineering are shown for all four
patients. Each point is the result for a single replicate sample. For all graphs, the line represents a linear model of degree 1 fitted to the points
while the Spearman rank correlation coefficient and its significance is shown in the top right corner. GAG, glycosaminoglycan; MSCs,
mesenchymal stem cells
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(Figure S2B). PN251 osteogenic scores had already declined to 0 by
10 population doublings and remained at 0 for higher doublings,
although the change was not statistically significant (Figure S2C).
Patient PN264 exhibited no observable osteogenic activity even at
the earliest number of population doublings (Figure S2D). Overall, the
individual osteogenic scores for the repeated assays were not signifi-
cantly correlated with the passage number of the MSCs used (Fig-
ure S2E); however, the different patterns observed with each of the
patients are indicative of a gradual, if variable decline in osteogenesis
with in vitro aging of the cells.
The adipogenic potential of MSCs was tested in monolayer cul-
ture by semiquantitative analysis of the staining for Oil-Red-O. Typical
images of the staining patterns and the scoring systems used are
shown in Figure S3. For patient PN251, there was a small but signifi-
cant fall in adipogenic potential with cumulative population doublings
(Figure S4C). whereas there was no significant change for the other
three patients (Figure S4A-C). Overall, the individual adipogenic
scores for the repeated assays were not significantly correlated with
the passage number of the MSCs used (Figure S4E) and therefore only
very limited evidence for a fall in adipogenesis with in vitro aging of
the cells.
Collectively, these data indicate a clear loss of differentiation
potential of MSCs, with early passage cells tending to show full tri-lin-
eage potential and later passage cells tending to retain only
adipogenic potential or adipogenic plus osteogenic but not
chondrogenic potential. These data suggest that multipotential differ-
entiation is not a fundamental property of CD105+ve, CD90+ve,
CD34−ve, CD45−ve MSCs, but rather a feature of freshly isolated
MSCs that is lost with cell expansion in vitro.
3.3 | Trophic repair by MSCs is maintained with
increasing passage
We used meniscal cartilage integration and suppression of T-cell pro-
liferation as assays relating to different aspects of trophic repair.
F IGURE 4 Trophic repair of meniscal cartilage and immunoregulation by MSCs from four patients at multiple passages. For trophic repair of
meniscal cartilage, undifferentiated MSCs were seeded onto a collagen scaffolds, inserted between two pieces of sheep meniscus, clipped
together, and cultured for 30 days. Histomorphometry was used to measure the degree of integration between the two pieces of meniscal tissue.
A-C, Typical examples of high, medium, and poor integration of meniscal tissue. Integration was measured in between the arrows. Scale
bars = 1 mm. D-G, The relationship between % integration of meniscal tissue and the population doublings of MSCs are shown for each of the
patients. For all the graphs, each point shows the mean value of multiple experimental replicates using cells from one patient at a single passage.
H, The relationship between % integration of meniscal tissue and the passage number of MSCs is shown for all four patients. Each point is the
result for a single replicate sample. For all correlation graphs (A-H), the line represents a linear model of degree 1 fitted to the points while the
Spearman rank correlation coefficient and its significance is shown in the top right corner. I, Immunoregulation was determined as the
% inhibition of T-cell proliferation, measured as the loss of Cell-Trace Violet from labeled cells, quantified by fluorescence-activated cell sorting.
Each point is the result for pooled triplicate wells. MSCs, mesenchymal stem cells
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The in vitro integration of two pieces of meniscal cartilage by
MSCs was based on our previous studies of this system in vitro, in an
in vivo sheep model and in patients with torn meniscus.27 MSCs from
all four patients at each of 17 passages were tested for their potency
in our meniscal repair potency assay. The variation in % integration of
meniscus in these studies was in the same range as previously
described, as illustrated in typical histological images (Figure 4A-C). In
contrast to our observations of tri-potential differentiation (see
above), there was no significant change in the mean potency of
meniscal repair with cumulative population doublings for any of the
four patients (Figure 4D-G). Furthermore, the % integration measured
for the individual meniscal constructs showed no correlation with the
passage number of the MSCs used (Figure 4H).
As well as stimulating tissue repair responses, MSCs are also
able to suppress immunity through inhibition of T-cell proliferation
and other mechanisms. We therefore measured the % inhibition of
T-cell proliferation by MSCs from selected passages for all four
patients. As with meniscal repair, there was no significant change in
the immunoregulatory capacity of MSCs with increasing passage
(Figure 4I).
Taken together, our observations of trophic repair indicate that
the protective and reparative effects of MSCs are a fundamental fea-
ture of CD105+ve, CD90+ve, CD34−ve, CD45−ve MSCs, that is
retained even after extensive expansion in vitro.
3.3.1 | Transcriptomics and proteomics data show
significant differences over passage that can be linked
to loss of multipotency
We reserved mRNA from the undifferentiated MSCs of all four
patients at each passage. Based on growth and differentiation charac-
teristics, we selected mRNA from passages P1, P5, P10, and P15 for
gene array comparison. For each of these passages, we also collected
conditioned medium for proteomic comparison. The genomic and pro-
teomic data were combined and analyzed for patterns of change in
F IGURE 5 Transcriptomics and proteomics. A, Overview of analytical steps performed. Transcriptomics and proteomics data were processed
according to data standards and integrated. The integrated data were further analyzed by Ingenuity Pathway Analysis to identify key genes and
proteins that change over passage and map them to biological functions and predict possible upstream regulators (see Figures 6 and 7). B, PCA
score plot of first two principal components of all genes and proteins. There is a segregation of patients (see blue and orange ellipses) that can
also be linked to changes in osteogenic capabilities (see Figure S2), while changes related to passage are capture mainly in PC2. C, Venn diagram
of significant variables after two-way analysis of variance revealing 338 genes and proteins that vary significantly and independently of the
patient group variation. D, PCA of the 338 significant variables over passage. Shown the score plot of the first two principal components
(capturing approximately 70% of variance). As expected, there is a marked segregation over passage. Heatmap of scaled data from the 338
significant proteins and genes that are represented in rows and clustered via Ward hierarchical clustering. Columns represent biological samples,
each column is a patient sample and they are ordered by passage with red being passage 1, green passage 5, turquoise passage 10, and purple
passage 15. PCA, principal component analysis
10
related genes and proteins. The methodological approach to trans-
criptomic and proteomic analysis is illustrated in Figure 5A. Data
structure was appraised via PCA. A score plot of the first two principal
components is shown in Figure 5B. The changes captured over pas-
sage are accounted for in PC2 while PC1 captures considerable varia-
tion between patients which can be stratified in two groups (shown
with blue and orange ellipses). These two groups of patients also
show differences in osteogenic capabilities (see above). With the aim
of identifying genes and proteins changing solely over passage, inde-
pendently of this patient variability, we performed a two-way ANOVA
for each variable, as described in the Section 2. Figure 5C shows the
significant variables of these tests. Only 338 genes and proteins are
significant uniquely over passage, independently of patient to patient
variation or any related iteration. These 338 genes and proteins were
used to calculate PCA, of which the first two principal components
are shown in Figure 5D together with a heatmap of the 338 variables
selected. As expected, these genes and proteins show a very clear
separation of all the patient samples by passage with a subset
decreasing their expression/abundance over passage (top half of the
heatmap) while others increase their expression/abundance (bottom
half of the heatmap).
For each of these 338 significant proteins and genes, we calcu-
lated the fold change with respect to passage 1 and analyzed these
data with Ingenuity Pathway Analysis (IPA) (QIAGEN, Inc., https://
www.qiagenbioinformatics.com/products/ingenuity-pathway-
analysis). IPA's core analysis, overlaid with the global molecular net-
work within the software resulted in the identification of a number of
canonical pathways, functions, and upstream regulators found to be
significantly over-represented within this list and therefore linked to
the loss of multipotential differentiation capacity of the cells. The larg-
est and most significant change was in the cell-cycle master regulator
FOXM1 gene pathway, with clear evidence from transcriptomic data
for downregulation of the FOXM1 gene itself (Figure 6A) and with six
out of seven of its downstream effectors also predicted by IPA to be
downregulated (Figure 6B). Other upstream regulators predicted to be
deactivated were the prostaglandin receptor PTGER2, and members
of the Vascular endothelial growth factor (VEGF) family, while
upstream regulators that were also predicted to be positively acti-
vated over passage included the proliferation regulator NUPR and the
cytoskeleton regulator MYOC. Quantitative data from our trans-
criptomic analyses and the associated IPA predictions of changes in
the downstream effectors of these regulators are shown in Figure S5;
F IGURE 6 Ingenuity Pathway Analysis of integrated transcriptomics and proteomics data. A, Ingenuity pathway analysis identified FOXM1
and four other master regulators genes (see Figure S5) that vary with increasing passage number. FOXM1 data from transcriptomics analysis
show inhibition of gene expression with increasing passage number. Each bar is the mean ± SEM for results using MSCs from each of the four
patients. B, Ingenuity pathway analysis of the integrated transcriptomics and proteomics data set predicts inhibition of five out of six of the
identified downstream regulators in the FOXM1 canonical pathway. C, Ingenuity pathway analysis identified multiple genes and proteins that
mapped to the search terms “Cell Movement,” “Cell Migration,” or “Wound Healing.” Most of these identified genes and proteins did not vary
significantly over passage as determined by analysis of variance. The most highly expressed genes and proteins are listed for each of the search
terms. D, CXCL12 data from transcriptomics analysis show continuous gene expression with increasing passage number. Each bar is the
mean ± SEM for results using MSCs from each of the four patients. E, CXCL12 data from proteomics analysis show continuous protein secretion
with increasing passage number. Each bar is the mean ± SEM for results using MSCs from each of the four patients. MSCs, mesenchymal stem
cells
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however, none of the changes and predicted downstream effects
were as clear-cut as for FOXM1.
3.4 | Regulators of cell migration and wound
healing can be linked to the trophic properties
of MSCs
As shown in Figure 4, the trophic repair capacity of MSCs remains
unchanged with increasing passage. With the aim of further investi-
gating this phenomenon, we hypothesized that (a) the proteins and
genes involved in regulating this function would not present a signifi-
cant change in abundance/expression over passage and (b) functions
related to cell movement, cell migration, and wound healing are likely
to be mechanistically involved in trophic repair. To investigate this
hypothesis, we used the IPA database to identify the proteins and
genes involved within the three terms listed above. Then we mapped
those lists to our data, extracted overlapping variables, and appraised
their significance over passage. The large majority of the proteins and
genes mapping to these search-terms were found to be unchanged
over passage and expressed at a consistent level across all four pas-
sages of our MSC cultures (Figure 6B), supporting the hypothesis that
genes and proteins expected to be necessary for trophic repair con-
tinue to be expressed in aging cells, when multipotent differentiation
capacity has been lost but trophic repair capacity remains high. We
considered CXCL12 (also called stromal cell-derived factor 1) to be of
particular importance at it is associated with all three of our search
terms (Figure 6C) and was expressed consistently highly at both gene
and protein level (Figure 6D,E).
3.5 | Marker genes and proteins
The IPA analysis outlined above demonstrated downregulation of the
FOXM1 canonical pathway with increasing passage/loss of
multipotent differentiation and continuous expression of CXCL12 and
other cell migration and wound healing genes and proteins with
increasing passage. However, we consider it necessary also to identify
genes and proteins that may not be part of canonical pathways or
gene/protein families, but that can be used as specific markers of
F IGURE 7 Gene and protein markers of the in vitro MSC aging process. The MMP13 gene was selected as a marker of early passage cells
which is lost with aging of MSCs in vitro while secretion of the TIMP-1 protein was selected as a marker of MSCs that is independent of in vitro
aging. A, MMP13 data from transcriptomics analysis show decreasing gene expression with increasing passage number. Each bar is the
mean ± SEM for results using MSCs from each of the four patients. B, MMP13 data from quantitative polymerase chain reaction analysis shows
decreasing gene expression with increasing passage number. Each bar is the mean ± SEM for results using MSCs from each of the four patients.
C, TIMP-1 data from proteomics analysis show continuous protein secretion with increasing passage number. Each bar is the mean ± SEM for
results using MSCs from each of the four patients. D, TIMP-1 data from enzyme linked immunosorbent assay analysis show continuous protein
secretion with increasing passage number. Each bar is the mean ± SEM for results using MSCs from each of the four patients. E, enzyme linked
immunosorbent assay analysis of TIMP-1 secreted by MSC/collagen scaffold constructs shows continuous protein secretion with increasing
passage number for fresh constructs but reduced secretion from constructs that have been freeze-thawed under conditions that reduce their
viability. For each cell source, the result is shown for one fresh compared with one frozen construct. MSCs, mesenchymal stem cells
12
cellular aging in vitro. Such markers would aid in comparison of stud-
ies of cells from one laboratory to another or in determining the func-
tionality of an MSC population being used for therapeutic purposes.
We therefore analyzed the gene array and protein data to identify
candidate markers.
Within the significant variable genes identified by transcriptomic
analysis, there was a significant decrease with increasing passage in
the gene for matrix metalloproteinase 13 (MMP13; Collagenase 3;
Figure 7A and Table S2) and a significant increase with increasing pas-
sage in the gene for Insulin-like growth factor binding protein 5 (IGF-
binding protein 5; Table S2). There was no significant change in other
MMP genes (Table S2) or IGFBP genes (Table S3), nor in any of the
genes of the transforming growth factor family (Table S4). Because
the transcriptomic data indicated that the rate of fall in MMP13 gene
expression with passage mirrored closely the fall in chondrogenic
potential (cf Figure 7A with Figure 3), we went on to validate these
results using quantitative PCR to determine more accurately the
changes in MMP13 gene expression with increasing passage. The
results confirm a continuous decline in MMP13 gene expression with
increasing passage (Figure 7B), demonstrating that loss of MMP13
gene expression could be used to help determine the extent to which
MSCs have aged through in vitro proliferation.
Within the proteomic data set, we identified those proteins
expressed at highest abundance at all passages (Table S5). The most
abundant of these proteins was metalloproteinase inhibitor 1 (tissue
inhibitor of metalloproteinase 1 [TIMP1]; Table S5 and Figure 7C). We
went on to validate these results using an ELISA kit assay to deter-
mine more accurately the changes in TIMP-1 protein secretion with
increasing passage (Figure 7D), demonstrating that expression of
TIMP-1 is a defining characteristic of MSCs, irrespective of the extent
to which they have aged through in vitro proliferation. Furthermore,
when MSCs were seeded onto collagen scaffolds and cultured for
24 hours, the cells continued to secrete high levels of MSCs from the
cell/scaffold constructs into their culture medium; however, if the
constructs were freeze-thawed under conditions that reduced their
viability, the secreted TIMP levels were substantially reduced
(Figure 7E).
These results indicate that MMP13+, TIMP1-secretinghigh MSCs
can be used as the basis of injectable therapies for osteaoarthritis that
are intended to act primarily through engraftment and chondrogenic
differentiation. In contrast, MMP13−, TIMP1-secretinghigh MSCs can
be used for OA therapies that are intended to act primarily through
trophic repair.
4 | DISCUSSION
We have identified two functional markers relating to MSC aging
in vitro, namely the MMP13 (Collagenase 3) gene, which is down-
regulated with increasing passage, and TIMP-1 protein, which is the
most abundant protein in the secretome at all passages. It is particu-
larly interesting that these two markers, which were identified inde-
pendently of each other (one from transcriptomics data and one form
proteomics), are biologically related to each other as TIMP-1 is an
inhibitor of MMP13 as well as other metalloproteinases. This relation-
ship is important because it could explain how production of a cata-
bolic proteinase (MMP13) correlates to an anabolic capacity of MSCs
(chondrogenesis). The very high levels of TIMP-1 produced by
undifferentiated MSCs at all passages will most likely inhibit any acti-
vated MMP13, rendering it catabolically inert. In an OA cell therapy
context, TIMP-1 protein secretion could be used as a specific marker
of MSC identity and viability as it is constitutively expressed at very
high levels at all passages whether growing on tissue culture plastic or
seeded into three-dimensional scaffolds. MMP13 gene expression
could be used as a functional marker to distinguish chondrogenic
MSCs from those that have good trophic capacity but poor
chondrogenic capacity.
These results also have important implications for the strategies
that should be used in the development of injectable OA therapies.
Since MMP13+, TIMP1-secretinghigh MSCs were lost as early as pas-
sage 5, it seems likely that OA therapies that are intended to act
through engraftment and chondrogenic differentiation will be
restricted to the use of autologous cells, because viable allogenic
products would require far more extensive expansion. While we can-
not rule out the possibility that alternative culture condition to those
used here could be identified as a method of sustaining the
chondrogenic phenotype even after in vitro aging, the present data
nevertheless lead us to conclude that allogeneic injectable stem cell
therapies for OA should rather focus on the use of MMP13−, TIMP1-
secretinghigh MSCs acting through trophic repair mechanisms.
Our results also have important biological implications. They
clearly indicate that the loss of multipotent differentiation capacity of
MSCs with extensive passaging in vitro cannot be the result of a gen-
eralized loss of cell function as the MSCs senesce, since another
important property of MSCs, trophic repair, is not significantly
reduced even after a very high number of population doublings and
reduced chondrogenic differentiation capacity was observed many
passages before cessation of proliferation. Furthermore, families of
genes and proteins from a range of critical signaling pathways show
clear changes that correlate with increasing passage number and loss
of differentiation, whereas genes and proteins known to be involved
with wound repair and cell movement/migration do not vary signifi-
cantly with increasing passage number. Downregulation of the
Forkhead Box M1 (FOXM1) canonical pathway showed a clear rela-
tionship to passage number, indicating a potential role for FOXM1 in
the maintenance and then loss of multipotency. This observation is
consistent with previous studies of its biological function. It is a proto-
oncogene that is a key master regulator in the survival of cancer stem
cells.48,49 It has also been shown to be highly expressed in multipotent
and pluripotent stem cells and to be critical to the maintenance of
stem cell potency50,51 and to the induction of pluripotency through
reprogramming.52 CXCL12 (also known as SDF-1) was found to be
associated with all three of our search terms related to trophic repair
and its gene and protein levels were maintained even at very late pas-
sage numbers, indicating a potential role for CXCL12 in MSC-medi-
ated trophic repair. This observation is consistent with previous
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studies which have demonstrated its critical role in MSC-mediated
induction of spinal cord repair53 and myocardial repair,54 as well as
enhancing nerve cell survival in vitro55 and mediating trophism
between endothelial cells and tumor cells.56 We have identified
FOXM1 and CXCL12 through combined proteomic and genomic anal-
ysis, but while this in silico approach is a powerful tool, any mechanis-
tic involvement of these regulators must await experimental
confirmation.
Previous studies have clearly shown that multipotency of MSCs
declines with both in vitro and in vivo aging.33-39 Our observation
here that chondrogenesis declines, osteogenesis tends to decline, but
adipogenesis is retained at higher passage number is in agreement
with the work of Yang et al.34 Muraglia et al36 also showed a loss of
multipotent differentiation with passage, but in their experiments,
osteogenesis was retained with early loss of adipogenesis. However,
they were working with clonal MSC cell-lines whereas the work
reported here and by Yang et al investigated the whole MSC
population.
Haynesworth et al first described the unique cytokine expression
pattern of MSCs57 and they demonstrated a reduction in cytokine
production after stimulating differentiation using dexamethasone. A
decade later, Caplan and Dennis coined the term “trophic effect”
which they defined as “those chemotactic, mitotic, and differentia-
tion-modulating effects which emanate from cells as bioactive factors
that exert their effects primarily on neighboring cells and whose
effects never result in differentiation of the producer cell”.22 They
cited, as a typical example of this effect, the support provided by
MSCs in the bone marrow niche for growth and differentiation of
hematopoietic cells. They also summarized evidence for MSCs provid-
ing trophic support in a range of cell therapy settings including the
treatment of stroke, myocardial infarction, and meniscal cartilage
regeneration. Numerous other studies have gone on to describe the
importance of MSC-induced trophic repair.20,22-25 We exploited the
trophic effects of MSCs in devising a new method of treating fresh
meniscal cartilage tears using a stem cell/collagen-scaffold implant to
promote integration of the damaged tissue. Our original in vitro stud-
ies demonstrated that the method depends on cell migration from the
implant into surrounding tissue and interaction with the endogenous
meniscal cells.26,46 Importantly, we found that MSCs that have been
stimulated with transforming growth factor-ß to undergo
chondrogenic differentiation are much less potent at promoting
meniscal repair than the undifferentiated MSCs.26 We went on to
describe the use of undifferentiated MSCs seeded on a collagen scaf-
fold to repair meniscal injury in a sheep preclinical model and in a first
in human trial.27 In the current study, we used our in vitro semiquanti-
tative meniscal cartilage integration assay26 as a model for trophic
repair and made the very surprising observation that MSCs that have
been cultured for up to 30 passages retain the same capacity for tro-
phic repair as very early passage cells. These functional data were
supported by our analysis of genes and proteins involved with cell
movement and migration and with wound healing, showing that unlike
those linked to differentiation, there was no significant change in their
expression with increasing passage.
Another aspect of MSC trophism is the immunoregulatory effects
of MSCs. Although a range of mechanisms are involved, it is clear that
inhibition of T-cell proliferation is a critical component of their sup-
pressive activity.9,24,28-31 Human T cells can be strongly stimulated to
proliferate using a combination of anti-CD3 and anti-CD28 anti-
bodies.58 Their rate of proliferation can be monitored by covalently
labeling intracellular molecules with a fluorescent dye that is then
diluted out by 50% with each cell division, tracked by FACS.59 Adding
MSCs into cultures of labeled, stimulated T cells suppresses the lym-
phocyte proliferation, so prolonging the accumulation of the dye.9 In
the current study, we have used this method to measure the immuno-
regulatory effects of MSCs at early and late passage and found no loss
of potency with increasing passage. For human MSCs, the mechanism
of T-cell suppression has been described as involving indoleamine 2,3-
dioxygenase-mediated tryptophan degradation.60 Taken together,
these results demonstrate that, as with trophic repair, immunoregula-
tion is a fundamental property of MSCs that is not lost with increasing
passage.
Previous studies have proposed that the loss of multipotent dif-
ferentiation capacity of MSCs with increasing passage is related to
progression of the cells to a senescent end-state.33-36 However, the
results described here demonstrate that even after extensive passag-
ing in vitro, there is no apparent loss of trophic repair. The term “Mes-
enchymal Stem Cells” was coined by Caplan,1 who went on to
describe MSCs as “An injury Drugstore”23 and more recently advo-
cated a change in their name to “Medicinal Signaling Cells”.61 Other
studies have questioned the definition of MSCs as stem cells because
of the lack of rigorous confirmatory biological evidence,20,25,31,62,63
with all of these studies calling for more experimental data before
reaching a conclusion on the nomenclature. Others have been more
forthright in concluding that MSCs are not stem cells and have called
for an immediate change in nomenclature, in order to avoid the over-
hyped marketing of MSCs as “miracle cures.”64-66 Prockop empha-
sized that the essence of a stem cell should not be determined by its
status at a single point in time.25 In this study, we have investigated
the in vitro differentiation and trophic behavior of MSCs across many
passages over time and in this way, have reached the conclusion that
the property of multipotency is relatively transient whereas the tro-
phic effects of these cells is apparently permanent all the way through
to the time of growth arrest.
5 | CONCLUSION
These studies demonstrate that the development of injectable MSC
therapies for OA must take into account the transient nature of
chondrogenic potency relative to their sustained trophic potency with
increasing passage and specific strategies should be adopted to
exploit one or other of these mechanisms of action.
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